TABLE 4.

Effect of single-dose oral treatment with HDP-CDV or ODE-CDV on mortality of BALB/c mice inoculated i.p. with MCMV

Expt and time of initiation	Treatment (mg/kg)a	No. of mice died/total no. (%)	Mortality result P valueb	MDDc	MDD P valueb
1
24 h	Placebo	14/15 (93)		5.5
	HDP-CDV, 30	0/15 (0)	<0.001
	HDP-CDV, 10	0/15 (0)	<0.001
	HDP-CDV, 3	0/15 (0)	<0.001
48 h	Placebo	12/15 (80)		4.9
	HDP-CDV, 30	1/15 (7)	<0.001	2.0	0.05
	HDP-CDV, 10	2/15 (13)	0.001	3.0	0.01
	HDP-CDV, 3	0/15 (0)	<0.001
72 h	Placebo	14/15 (93)		5.1
	HDP-CDV, 30	7/15 (47)	0.01	5.9	NS
	HDP-CDV, 10	10/15 (67)	NS	6.8	NS
	HDP-CDV, 3	13/15 (87)	NS	5.6	NS
2
24 h	Placebo	12/15 (80)		5.1
	CDV, 30	0/15 (0)	<0.001
	ODE-CDV, 30	1/15 (7)	<0.01	2.0	NS
	ODE-CDV, 10	0/15 (0)	<0.001
	ODE-CDV, 3	1/15 (7)	<0.001	3.0	NS
48 h	Placebo	15/15 (100)		5.0	NS
	CDV, 30	2/15 (13)	0.001	9.5	NS
	ODE-CDV, 30	15/15 (100)	NS	7.0	<0.001
	ODE-CDV, 10	4/15 (27)	<0.001	3.8	<0.01
	ODE-CDV, 3	1/15 (7)	<0.001	5.0	NS
72 h	Placebo	8/12 (67)		5.0
	CDV, 30	0/15 (0)	<0.001
	ODE-CDV, 30	11/14 (79)	NS	7.2	0.01
	ODE-CDV, 10	5/13 (38)	NS	5.2	NS
	ODE-CDV, 3	11/15 (73)	NS	5.0	NS

^aCDV was prepared in sterile saline and delivered i.p. in 0.1-ml doses. HDP-CDV or ODE-CDV was prepared in deionized water and delivered orally in 0.2-ml doses. Animals were treated once beginning 24, 48, or 72 h after viral inoculation.

^bP values were determined by comparing results for drug treatment groups with results for placebo control groups. NS, not significant compared to placebo controls.

^cMDD, mean day of death.